Results 91 to 100 of about 2,028 (216)

78P Exploring ecDNA heterogeneity and evolution in non-small cell lung cancer

ESMO Open
J. Kittel, Chris Bailey, Oriol Pich, Kerstin Thol, C. Lombardelli, N. Sharma, Georgia Stavrou, Nnennaya Kanu, Mariam Jamal‐Hanjani, Charles Swanton   +9 more
openalex   +2 more sources

CytoCellDB: a comprehensive resource for exploring extrachromosomal DNA in cancer cell lines [PDF]

Recently, the cancer community has gained a heightened awareness of the roles of extrachromosomal DNA (ecDNA) in cancer proliferation, drug resistance and epigenetic remodeling. However, a hindrance to studying ecDNA is the lack of available cancer model
Brunk, Elizabeth, Cannon, Danielle, Chen, Jingting, Fessler, Jacob, Ford, Christina, Goble, Kohen, Gulec, Saygin, Haase, Santiago, Mehta, Aarav, Smyers, Nathan, Ting, Stephanie, Wang, Yue, Yi, Hong   +12 more
core   +2 more sources

Mitotic clustering of pulverized chromosomes from micronuclei [PDF]

, 2023
Complex genome rearrangements can be generated by the catastrophic pulverization of missegregated chromosomes trapped within micronuclei through a process known as chromothripsis1–5. As each chromosome contains a single centromere, it remains unclear how
Bakhoum, Samuel F., Bronder, Daniel, Cortés-Ciriano, Isidro, Dahiya, Rashmi, Engel, Justin L., Guyer, Alison, Hu, Qing, Lin, Yu-Fen, Ly, Peter, Maurais, Elizabeth G., Mazzagatti, Alice, Nguyen, Giaochau, Sanders, Jacob T., Valle-Inclán, Jose Espejo   +13 more
core   +1 more source

CoRAL accurately resolves extrachromosomal DNA genome structures with long-read sequencing. [PDF]

Genome Res
Extrachromosomal DNA (ecDNA) is a central mechanism for focal oncogene amplification in cancer, occurring in ∼15% of early-stage cancers and ∼30% of late-stage cancers.
Zhu K, Jones MG, Luebeck J, Bu X, Yi H, Hung KL, Wong IT, Zhang S, Mischel PS, Chang HY, Bafna V.   +10 more
europepmc   +3 more sources

Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2‐Mediated Transcriptional Network in Multiple Myeloma

Advanced Science, Volume 12, Issue 21, June 5, 2025.
Enhancer eccANKRD28‐manipulated MM cells have been demonstrated to facilitate drug resistance and promote MM progression by activating the key transcription factor, POU2F2. POU2F2 interacts with sequence‐specific eccANKRD28 as well as RUNX1 and RUNX2 motifs to form the protein complex, which activates the promoter of oncogenes (IRF4, JUNB, IKZF3, et al.
Binzhen Chen, Jia Liu, Yaoxin Zhang, Changming Shi, Di Zhu, Guoqiang Zhang, Fei Xiao, Lu Zhong, Minyue Zhang, Lai Guan Ng, Honghui Huang, Tingting Lu, Jian Hou   +12 more
wiley   +1 more source

The Citrullination-Neutrophil Extracellular Trap Axis in Chronic Diseases

Journal of Innate Immunity, 2022
Citrullination of proteins is crucial for the formation of neutrophil extracellular traps (NETs) – strands of nuclear DNA expulsed in the extracellular environment along with antimicrobial proteins in order to halt the spread of pathogens. Paradoxically,
Martin Maronek, Roman Gardlik
doaj   +1 more source

Linked-read based analysis of the medulloblastoma genome

Frontiers in Oncology, 2023
IntroductionMedulloblastoma is the most common type of malignant pediatric brain tumor with group 4 medulloblastomas (G4 MBs) accounting for 40% of cases. However, the molecular mechanisms that underlie this subgroup are still poorly understood.
Melissa Zwaig, Michael J. Johnston, John J.Y. Lee, John J.Y. Lee, Hamza Farooq, Marco Gallo, Nada Jabado, Nada Jabado, Nada Jabado, Michael D. Taylor, Michael D. Taylor, Jiannis Ragoussis   +11 more
doaj   +1 more source

Environmental Drivers of Malignant Clonal Selection in Precancerous Lesion Evolution

Cell Proliferation, Volume 58, Issue 5, May 2025.
ABSTRACT Somatic mutations accumulation and subsequent malignant clonal selection are the processes that lead to cancer. The intricacy includes exposure to carcinogens as well as the ways in which these exposures interact with genetic, polygenic, or epigenetic predispositions.
Yancheng Lai, Shaosen Zhang
wiley   +1 more source

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Thoracic Cancer, 2022
Background ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving bypass signaling.
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele   +13 more
doaj   +1 more source

Patient‐derived xenograft model in cancer: establishment and applications

MedComm, Volume 6, Issue 2, February 2025.
This review presents the establishment and application of patient‐derived xenograft (PDX) models, underscoring their extensive application in various therapeutic strategies including chemotherapy, targeted therapy, delivery systems, combination therapy, antibody–drug conjugates, and radiotherapy.
Ao Gu, Jiatong Li, Meng‐Yao Li, Yingbin Liu   +3 more
wiley   +1 more source